+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lyrica"

CNS Therapeutics - Global Strategic Business Report - Product Thumbnail Image

CNS Therapeutics - Global Strategic Business Report

  • Report
  • April 2025
  • 898 Pages
  • Global
From
From
Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2024 - Product Thumbnail Image

Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 60 Pages
  • Global
From
From
From
Lyrica - API Insight, 2022 - Product Thumbnail Image

Lyrica - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
  • 13 Results (Page 1 of 1)
Loading Indicator

Lyrica (pregabalin) is a central nervous system (CNS) drug used to treat neuropathic pain, fibromyalgia, and generalized anxiety disorder. It is an anticonvulsant and anxiolytic drug that works by binding to certain calcium channels in the brain, reducing the release of neurotransmitters that cause pain and anxiety. Lyrica is also used to treat partial onset seizures in adults with epilepsy. It is available in both immediate-release and extended-release formulations. Lyrica is marketed by Pfizer, Inc. in the United States and by various generic manufacturers in other countries. It is available in capsule, tablet, and oral solution forms. Lyrica is also available in combination with other drugs, such as gabapentin and duloxetine. Other companies in the Lyrica market include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more